恩度联合脂质体紫杉醇及顺铂治疗肺癌肝转移的疗效观察

Efficacy of Endo Combined with Liposome Paclitaxel and Cisplatin in the Treatment of Liver Metastases from Lung Cancer

目的:观察恩度联合脂质体紫杉醇及顺铂治疗肺癌肝转移的临床疗效。方法:选取2018年1月至2019年12月于我院收治且行化疗治疗的非小细胞癌(non-small cell lung cancer,NSCLC)患者125例,基于随机数字表简单随机分为观察组与对照组。其中,观察组:行“恩度+脂质体紫杉醇+顺铂”治疗,有67例;对照组:行“脂质体紫杉醇+顺铂”治疗,有58例。比较两组原发病灶及肝转移灶的临床疗效,同时记录两组不良反应发生情况,并随访1年以上记录两组患者无进展生存期(Progression-free survival,PFS)。结果:就肺原发灶疗效而言,两组整体疗效及ORR、DCR比较均不存在显著差异(P>0.05)。就肝转移灶疗效而言,相较于对照组,观察组整体临床疗效更优(P<0.05);观察组ORR(38.81%vs 20.69%)、DCR(85.07%vs 68.97%)均明显更高(P<0.05)。相较于对照组,观察组PFS明显更长(P<0.05);两组不良反应发生率比较无显著差异(P>0.05)。结论:相较于“脂质体紫杉醇+顺铂”治疗方式,恩度联合脂质体紫杉醇及顺铂应用于肺癌肝转移临床治疗的疗效更为显著,能够有效抑制肝转移,可明显提高患者无进展生存期,改善患者预后,具有临床应用价值。

Objective:To observe the clinical efficacy of Endo combined with liposomal paclitaxel and cisplatin in the treatment of liver metastases from lung cancer.Methods:A total of 125 patients with non-small cell lung cancer(NSCLC)who were admitted to our hospital from January 2018 to December 2019 and were treated with chemotherapy were randomly divided into observation group and control group based on the random number table.In the observation group,67 cases were treated with"Endo+liposomal paclitaxel+cisplatin";in the control group,58 cases were treated with"liposomal paclitaxel+cisplatin".The clinical efficacy of the primary lesions and liver metastases were compared between the two groups,and the occurrence of adverse reactions in the two groups was recorded at the same time,and the two groups were followed up for more than 1 year to record the progression-free survival(PFS).Results:In terms of the efficacy of primary lung lesions,there was no significant difference in overall efficacy,ORR and DCR between the two groups(P>0.05).In terms of the efficacy of liver metastases,compared with the control group,the observation group has better overall clinical efficacy(P<0.05);the observation group has significantly higher ORR(38.81%vs 20.69%)and DCR(85.07%vs 68.97%)(P<0.05).Compared with the control group,the PFS of the observation group was significantly longer(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Compared with the"liposomal paclitaxel+cisplatin"treatment,Endo combined with liposomal paclitaxel and cisplatin in the clinical treatment of lung cancer liver metastasis is more effective,and effectively inhibits liver metastasis,and it also significantly improves patients progression-free survival,improvs the prognosis of patients,and has clinical application value.